益生菌预防超重和肥胖孕妇妊娠期糖尿病:SPRING双盲随机对照试验
SPRING双盲随机对照试验在澳大利亚布里斯班纳入411名超重和肥胖孕妇,从孕中期给予益生菌(鼠李糖乳杆菌和动物双歧杆菌乳亚种)或安慰剂,评估28周OGTT诊断的GDM。益生菌组GDM发生率为18.4%,安慰剂组为12.3%(P=0.10),差异无统计学意义;益生菌未预防GDM,但益生菌组过度体重增长比例较低(32.5% vs 46%,P=0.01),小于胎龄儿发生率较低(2.4% vs 6.5%,P=0.042)。
要点
- 益生菌未能降低超重/肥胖孕妇GDM发生率(18.4% vs 12.3%,P=0.10)。
- 益生菌组空腹血糖略高(79.3 vs 77.5 mg/dL,P=0.049)。
- 益生菌组过度体重增长和小于胎龄儿比例较低,但为次要结局。
核心结论
- 本研究所用益生菌不能预防超重和肥胖孕妇的妊娠期糖尿病。
研究设计与样本
- 双盲随机对照试验,在澳大利亚布里斯班超重和肥胖孕妇中比较益生菌与安慰剂,从孕中期开始干预。
- 研究完成于411名妇女,益生菌组207例,安慰剂组204例。
主要发现
- GDM发生率益生菌组18.4%(38/207),安慰剂组12.3%(25/204),P=0.10。
- OGTT平均空腹血糖益生菌组79.3 mg/dL,安慰剂组77.5 mg/dL,P=0.049;1小时和2小时血糖相似。
- 子痫前期发生率益生菌组9.2%,安慰剂组4.9%,P=0.09。
- 过度体重增长益生菌组32.5%(55/169),安慰剂组46%(81/176),P=0.01。
- 小于胎龄儿(<第10百分位)发生率益生菌组2.4%(5/205),安慰剂组6.5%(13/199),P=0.042。
关键数值与推荐
- GDM诊断依据28周妊娠期口服葡萄糖耐量试验(OGTT)。
- 益生菌为鼠李糖乳杆菌和动物双歧杆菌乳亚种乳酸亚种。
临床怎么用
- 不应基于本研究结果使用益生菌来预防超重和肥胖孕妇的GDM。
- 益生菌对空腹血糖、过度体重增长和小于胎龄儿的影响需进一步研究验证。
局限性
- GDM发生率差异无统计学意义,研究可能不足以检测次要结局的差异。
- 干预仅从孕中期开始,未覆盖孕早期。
- 研究人群为澳大利亚布里斯班的超重和肥胖孕妇,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Given the role of gut microbiota in regulating metabolism, probiotics administered during pregnancy might prevent gestational diabetes mellitus (GDM). This question has not previously been studied in high-risk overweight and obese pregnant women. We aimed to determine whether probiotics (Lactobacillus rhamnosus and Bifidobacterium animalis subspecies lactis) administered from the second trimester in overweight and obese women prevent GDM as assessed by an oral glucose tolerance test (OGTT) at 28 weeks' gestation. Secondary outcomes included maternal and neonatal complications, maternal blood pressure and BMI, and infant body composition. RESEARCH DESIGN AND METHODS: This was a double-blind randomized controlled trial of probiotic versus placebo in overweight and obese pregnant women in Brisbane, Australia. RESULTS: The study was completed in 411 women. GDM occurred in 12.3% (25 of 204) in the placebo arm and 18.4% (38 of 207) in the probiotics arm (P = 0.10). At OGTT, mean fasting glucose was higher in women randomized to probiotics (79.3 mg/dL) compared with placebo (77.5 mg/dL) (P = 0.049). One- and two-hour glucose measures were similar. Preeclampsia occurred in 9.2% of women randomized to probiotics compared with 4.9% in the placebo arm (P = 0.09). Excessive weight gain occurred in 32.5% of women in the probiotics arm (55 of 169) compared with 46% in the placebo arm (81 of 176) (P = 0.01). Rates of small for gestational age (<10th percentile) were 2.4% in the probiotics arm (5 of 205) and 6.5% in the placebo arm (13 of 199) (P = 0.042). There were no differences in other secondary outcomes. CONCLUSIONS: The probiotics used in this study did not prevent GDM in overweight and obese pregnant women.
引用
- Callaway LK, McIntyre HD, Barrett HL, et al. Probiotics for the Prevention of Gestational Diabetes Mellitus in Overweight and Obese Women: Findings From the SPRING Double-Blind Randomized Controlled Trial. Diabetes Care. 2019. PMID: 30659070. doi:10.2337/dc18-2248
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。